Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA

References

• El-Serag HB. Hepatocellular carcinoma. New England J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra100168321992124
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Skolnick AA. Armed with epidemiologic research, China launches programs to prevent liver cancer. Jama. 1996;276(18):1458–1459.8903245
   PubMed Web of Science ®Google Scholar
• Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–779. doi:10.1586/17474124.2015.102836325827821
   PubMed Web of Science ®Google Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(12):1632–1651. doi:10.4254/wjh.v7.i12.163226140083
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Hester CA, Singal AG, Yopp AC. Management of hepatocellular in the United States. Chin Clin Oncol. 2017;6(2):21. doi:10.21037/cco28482674
   PubMed Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, Worns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–183. doi:10.1016/j.jhep.2017.03.00728323121
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterol. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-30662724531850
   PubMed Web of Science ®Google Scholar
• Zhang YS, Ma YL, Thakur K, et al. Molecular mechanism and inhibitory targets of dioscin in HepG2 cells. Food Chem Toxicol. 2018;120:143–154. doi:10.1016/j.fct.2018.07.01629990575
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang YS, Thakur K, et al. Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest. Food Chem Toxicol. 2018;120:407–417. doi:10.1016/j.fct.2018.07.04430055311
   PubMed Web of Science ®Google Scholar
• Liu Y, Cai Y, He C, Chen M, Li H. Anticancer properties and pharmaceutical applications of plumbagin: a review. Am J Chin Med. 2017;45(3):423–441. doi:10.1142/S0192415X1750026428359198
   PubMed Web of Science ®Google Scholar
• Panichayupakaranant P, Ahmad MI. Plumbagin and its role in chronic diseases. Adv Exp Med Biol. 2016;929:229–246. doi:10.1007/978-3-319-41342-6_1027771927
   PubMed Web of Science ®Google Scholar
• Cao YY, Yu J, Liu TT, et al. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling. Cell Death Dis. 2018;9(2):17. doi:10.1038/s41419-017-0068-629339720
   PubMed Web of Science ®Google Scholar
• Hafeez BB, Zhong W, Mustafa A, Fischer JW, Witkowsky O, Verma AK. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCepsilon, Stat3 and neuroendocrine markers. Carcinog. 2012;33(12):2586–2592. doi:10.1093/carcin/bgs291
   PubMed Web of Science ®Google Scholar
• Sugie S, Okamoto K, Rahman KM, et al. Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Letters. 1998;127(1–2):177–183.9619875
   PubMed Web of Science ®Google Scholar
• Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Letters. 2014;344(2):239–259. doi:10.1016/j.canlet.2013.11.00124280585
   PubMed Web of Science ®Google Scholar
• Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer. 2012;131(9):2175–2186. doi:10.1002/ijc.2747822322442
   PubMed Web of Science ®Google Scholar
• Prasad KV, Ao Z, Yoon Y, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Pro National Acad Sci USA. 1997;94(12):6346–6351.
   PubMed Web of Science ®Google Scholar
• Van Nostrand JL, Brisac A, Mello SS, Jacobs SB, Luong R, Attardi LD. The p53 target gene SIVA enables non-small cell lung cancer development. Cancer Discovery. 2015;5(6):622–635. doi:10.1158/2159-8290.CD-14-092125813352
   PubMed Web of Science ®Google Scholar
• Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60(4):855–865. doi:10.1016/j.jhep.2013.11.03124308993
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Ray EM, Sanoff HK. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocellular Carcinoma. 2017;4:131–138. doi:10.2147/JHC.S12436629184856
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Malonne H, Duez P, Vanhaelen-Fastre R, Vanhaelen M, Fontaine J. Cytotoxic constituents from Plumbago zeylanica. Fitoterapia. 2004;75(5):500–504. doi:10.1016/j.fitote.2004.03.00915261389
   PubMed Web of Science ®Google Scholar
• Huang SS, Deng JS, Lin JG, Lee CY, Huang GJ. Anti-inflammatory effects of trilinolein from Panax notoginseng through the suppression of NF-kappaB and MAPK expression and proinflammatory cytokine expression. Am J Chin Med. 2014;42(6):1485–1506. doi:10.1142/S0192415X1450093125482678
   PubMed Web of Science ®Google Scholar
• Kaewbumrung S, Panichayupakaranant P. Antibacterial activity of plumbagin derivative-rich Plumbago indica root extracts and chemical stability. Nat Product Res. 2014;28(11):835–837. doi:10.1080/14786419.2013.879585
   PubMed Web of Science ®Google Scholar
• Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008;68(21):9024–9032. doi:10.1158/0008-5472.CAN-08-249418974148
   PubMed Web of Science ®Google Scholar
• Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461–1473. doi:10.1038/onc.2016.30427617575
   PubMed Web of Science ®Google Scholar
• Li L, Tang P, Li S, et al. Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy. Med Oncol. 2017;34(10):180. doi:10.1007/s12032-017-1039-628918490
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–383. doi:10.3109/07853890.2014.91283624897931
   PubMed Web of Science ®Google Scholar
• Jacobs SB, Basak S, Murray JI, Pathak N, Attardi LD. Siva is an apoptosis-selective p53 target gene important for neuronal cell death. Cell Death Differ. 2007;14(7):1374–1385. doi:10.1038/sj.cdd.440212817464332
   PubMed Web of Science ®Google Scholar
• Higashitsuji H, Higashitsuji H, Itoh K, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005;8(1):75–87. doi:10.1016/j.ccr.2005.06.00616023600
   PubMed Web of Science ®Google Scholar
• Li N, Jiang P, Du W, et al. Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Pro National Acad Sci USA. 2011;108(31):12851–12856. doi:10.1073/pnas.1017372108
   PubMed Web of Science ®Google Scholar
• Fortin A, MacLaurin JG, Arbour N, et al. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. J Biol Chem. 2004;279(27):28706–28714. doi:10.1074/jbc.M40037620015105421
   PubMed Web of Science ®Google Scholar
• Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78(1):35–43.7518356
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905–909.1715094
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi:10.1016/j.cell.2006.01.01616469695
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends in Molecular Medicine. 2005;11(8):353–361. doi:10.1016/j.molmed.2005.06.00716002336
   PubMed Web of Science ®Google Scholar
• Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886–1918. doi:10.3390/ijms1302188622408430
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25(48):6436–6446. doi:10.1038/sj.onc.120988617041628
   PubMed Web of Science ®Google Scholar